Interestingly, FAK inhibitors, such as PF-00562271, have shown efficacy in preclinical models and are currently under clinical investigation, indicating the potential of targeting fibronectin–FAK interactions as a therapeutic approach in cancer (Supplementary Table S3; refs. 111–113). The gene discussed is PTK2; the disease is cancer.